MedPlus Health Services Limited has received two stay orders from appropriate authorities in Pune, Maharashtra against a suspension order, according to a regulatory filing dated April 28, 2026.

Regulatory Update Details

The company submitted this update under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing references earlier submissions made on February 4, 2026 and March 4, 2026, indicating an ongoing regulatory matter in Maharashtra.

Corporate Communication

The regulatory filing was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited. The company has made the documentation available on its official website at www.medplusindia.com , as well as on the stock exchange websites.

Company Information

MedPlus Health Services Limited operates from its registered office in Hyderabad, Telangana. The company maintains transparency in regulatory communications through proper disclosure channels as mandated by SEBI listing regulations.

The stay orders represent a significant development in the ongoing regulatory proceedings, providing temporary relief from the suspension orders that were the subject of earlier regulatory submissions.

Medplus Health Services has informed the stock exchanges that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses of stores situated in Karnataka. The disclosure was made to BSE Limited and National Stock Exchange of India Limited under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The orders were issued by the Assistant Director, Drugs Control Administration, Bangalore Circle - 3, Bangalore, Karnataka. The regulatory action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Details of Suspension Orders

The suspension orders affect stores with varying durations and potential financial impacts:

Regulatory Compliance

The suspension order was issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has ensured full transparency by making the information available on its website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited.

The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer of MedPlus Health Services Limited, on April 22, 2026, ensuring compliance with regulatory requirements for timely disclosure of material events.